Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Senores Pharmaceuticals Ltd (SENORES) is currently trading at 745.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Senores Pharmaceuticals Limited primarily engages in developing and manufacturing pharmaceuticals for regulated markets such as the US and Canada, along with emerging markets. It has built a robust regimen of ANDAs, facilitating entry in niche, high-complexity therapeutic areas. Significantly increased its portfolio to 46 approved ANDAs covering 137 strengths, reflecting a scaling up of operations and strategic market penetration. Expected launches from pending ANDAs promise further growth. The acquisition of a 75% stake in Apnar Pharmaceuticals has strengthened Senores' operational footprint in regulated markets, with benefits of existing approvals for generic formulations. The company has shown tremendous financial growth, evidenced by a 64% increase in total income in Q3FY26 YoY, supported by a focused strategy on regulated and emerging markets. Senores merges traditional pharma with modern strategies such as CDMO/CMO, optimizing both generic and branded sectors with increasing EBITDA margins through focused commercial plans.
Over the past 52 weeks, Senores Pharmaceuticals Ltd has traded between a low of ₹457.95 and a high of ₹876.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Senores Pharmaceuticals Ltd has a market capitalization of approximately 3,527.01. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Senores Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.31 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,527.01 Cr, Senores Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Senores Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Senores Pharmaceuticals Ltd is 34.31. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company expects to outperform its FY26 guidance due to strong operational run rates, incremental revenues from the newly acquired Apnar Pharma facility, and significant growth in emerging markets.
The acquisition has a total enterprise value of approximately ₹91 crore. This includes Senores taking over ₹76 crore in debt and liabilities, with the remaining ₹15 crore paid in cash.
Corporate Guarantee
Senores Pharmaceuticals Ltd issued a corporate guarantee up to USD 4,100,000 for credit facilities availed by its wholly‑owned US subsidiary Senores Pharmaceuticals Inc. from HDFC Bank; guarantee valid until facility closure or max 10 years and will be disclosed as a contingent liability.
Regulatory Filing
Senores Pharmaceuticals issued a corporate guarantee of up to USD 1,500,000 to HDFC Bank for additional credit facilities availed by its material subsidiary Havix Group Inc. (d/b/a Aavis Pharmaceuticals); guarantee valid up to closure or max 10 years and will be disclosed as a contingent liability.
Regulatory Filing
Senores Pharmaceuticals has issued a corporate guarantee up to USD 1,500,000 to HDFC Bank for additional credit facilities availed by its material US subsidiary Havix Group Inc (D/B/A Aavis Pharmaceuticals), disclosed as a contingent liability.
Bearish
3
Neutral
2
Bullish
9
Bearish
33
Neutral
2
Bullish
11
Bearish
30
Neutral
0
Bullish
2
Senores Pharmaceuticals Limited primarily engages in developing and manufacturing pharmaceuticals for regulated markets such as the US and Canada, along with emerging markets. It has built a robust regimen of ANDAs, facilitating entry in niche, high-complexity therapeutic areas.
Significantly increased its portfolio to 46 approved ANDAs covering 137 strengths, reflecting a scaling up of operations and strategic market penetration. Expected launches from pending ANDAs promise further growth.
The acquisition of a 75% stake in Apnar Pharmaceuticals has strengthened Senores' operational footprint in regulated markets, with benefits of existing approvals for generic formulations.
The company has shown tremendous financial growth, evidenced by a 64% increase in total income in Q3FY26 YoY, supported by a focused strategy on regulated and emerging markets.
Senores merges traditional pharma with modern strategies such as CDMO/CMO, optimizing both generic and branded sectors with increasing EBITDA margins through focused commercial plans.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
3,527 Cr
Moderate Risk
34.3
44.0
1.5
4.3
876.00
457.95
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
126.85 | 4,091 Cr | -15.36 | 0.00 | 0.00 | 77.47 | -181.73 | -83.09 | |
763.15 | 3,527 Cr | 34.31 | 4.33 | 0.00 | 10.70 | 12.41 | 7.98 | |
214.40 | 2,262 Cr | 21.10 | 2.00 | 0.23 | 9.68 | 14.69 | 8.17 | |
39.18 | 1,716 Cr | 59.36 | 156.72 | 0.03 | — | — | 0.00 | |
578.25 | 1,678 Cr | 41.07 | 4.91 | 0.79 | 16.57 | 22.53 | 13.16 | |
755.00 | 1,590 Cr | 24.05 | 2.98 | 0.76 | 12.60 | 16.43 | 8.20 | |
1535.45 | 1,311 Cr | 30.75 | 3.88 | 0.45 | 12.98 | 9.93 | 6.29 |
